Drug Type Small molecule drug |
Synonyms LXI 15029, LXI-15029, LXI15029 + [1] |
Target |
Mechanism mTORC1 inhibitors(Mammalian target of Rapamycin (mTORC1) inhibitors), mTORC2 inhibitors(mTOR Complex 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Molecular FormulaC26H30N6O3 |
InChIKeyLVPBYQVQBZLDAU-DZIBYMRMSA-N |
CAS Registry1567915-38-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced breast cancer | Phase 1 | CN | 12 Jun 2017 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 12 Jun 2017 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 12 Jun 2017 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 12 Jun 2017 | |
HER2-negative breast cancer | Phase 1 | CN | 12 Jun 2017 | |
HER2-negative breast cancer | Phase 1 | CN | 12 Jun 2017 | |
HER2-negative breast cancer | Phase 1 | CN | 12 Jun 2017 | |
Metastatic breast cancer | Phase 1 | CN | 12 Jun 2017 | |
Metastatic breast cancer | Phase 1 | CN | 12 Jun 2017 | |
Metastatic breast cancer | Phase 1 | CN | 12 Jun 2017 |
Not Applicable | - | ywmsicdpfy(mdmhthkxrd) = 20.8% nlkgmlandf (qjorswfimz ) View more | - | 06 Dec 2023 | |||